OTCPK:IPDQ.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has ImpediMed's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IPDQ.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

IPDQ.F

1.6%

US Medical Equipment

2.3%

US Market


1 Year Return

-54.5%

IPDQ.F

19.1%

US Medical Equipment

17.2%

US Market

Return vs Industry: IPDQ.F underperformed the US Medical Equipment industry which returned 17.1% over the past year.

Return vs Market: IPDQ.F underperformed the US Market which returned 15.8% over the past year.


Shareholder returns

IPDQ.FIndustryMarket
7 Day0%1.6%2.3%
30 Day-7.5%-2.3%-4.6%
90 Day-16.7%9.7%7.4%
1 Year-54.5%-54.5%20.1%19.1%19.8%17.2%
3 Year-92.1%-92.1%70.5%66.0%37.4%28.3%
5 Year-92.2%-92.2%145.9%127.1%83.8%63.0%

Price Volatility Vs. Market

How volatile is ImpediMed's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ImpediMed undervalued compared to its fair value and its price relative to the market?

2.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IPDQ.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IPDQ.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IPDQ.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: IPDQ.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IPDQ.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IPDQ.F is good value based on its PB Ratio (2.3x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is ImpediMed forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

46.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IPDQ.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IPDQ.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IPDQ.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IPDQ.F's revenue (45.5% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: IPDQ.F's revenue (45.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IPDQ.F is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has ImpediMed performed over the past 5 years?

-3.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IPDQ.F is currently unprofitable.

Growing Profit Margin: IPDQ.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IPDQ.F is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.

Accelerating Growth: Unable to compare IPDQ.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IPDQ.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: IPDQ.F has a negative Return on Equity (-78.13%), as it is currently unprofitable.


Next Steps

Financial Health

How is ImpediMed's financial position?


Financial Position Analysis

Short Term Liabilities: IPDQ.F's short term assets (A$25.5M) exceed its short term liabilities (A$5.1M).

Long Term Liabilities: IPDQ.F's short term assets (A$25.5M) exceed its long term liabilities (A$594.0K).


Debt to Equity History and Analysis

Debt Level: IPDQ.F is debt free.

Reducing Debt: IPDQ.F has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IPDQ.F has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: IPDQ.F is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is ImpediMed current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IPDQ.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IPDQ.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IPDQ.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IPDQ.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IPDQ.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Rick Carreon

8.17yrs

Tenure

AU$1,142,148

Compensation

Mr. Richard Carreon, also known as Rick, has been the Managing Director of ImpediMed Limited since May 9, 2015 and joined as its Chief Executive Officer and President since July 10, 2012. Mr. Carreon has e ...


CEO Compensation Analysis

Compensation vs Market: Rick's total compensation ($USD813.21K) is above average for companies of similar size in the US market ($USD601.03K).

Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Richard Carreon
MD, CEO8.17yrsAU$1.14m0.23%
A$ 106.6k
David Adams
Senior Vice President of Operations & Strategic Planning1.67yrsAU$640.19k0.081%
A$ 37.7k
Shashi Tripathi
Chief Technology Officer2.17yrsAU$654.39kno data
Dennis Schlaht
Senior Vice President of R&D and Technologyno dataAU$627.94k0.19%
A$ 86.6k
Catherine Kingsford
Senior Vice President of Medical Affairsno dataAU$474.66k0.37%
A$ 171.0k
Timothy Cruickshank
Chief Financial Officer0.50yrno datano data
Michael Bassett
Senior Vice President of Corporate & Strategic Developmentno datano datano data
Nancy Deisinger
Vice President of Human Resources1.67yrsno datano data
Frank Vicini
Chief Medical Officer6yrsno datano data
Leanne Ralph
Company Secretary5.67yrsno datano data
Walton Taylor
Medical Director10.5yrsno datano data

3.9yrs

Average Tenure

Experienced Management: IPDQ.F's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Richard Carreon
MD, CEO8.17yrsAU$1.14m0.23%
A$ 106.6k
Scott Ward
Independent Non-Executive Chairman2.83yrsAU$161.34k0.20%
A$ 92.4k
Robert Graham
Independent Non-Executive Director2.83yrsAU$69.29k0.093%
A$ 43.3k
Donald Williams
Independent Non-Executive Director3.5yrsAU$115.77k0.14%
A$ 64.1k
Judith Downes
Non-Executive Director3.42yrsAU$76.99k0.13%
A$ 59.5k
Amit Patel
Non-Executive Director3.5yrsAU$94.72k0.11%
A$ 51.6k
David Anderson
Non-Executive Director0.33yrAU$10.29k0.015%
A$ 7.0k

3.4yrs

Average Tenure

63.5yo

Average Age

Experienced Board: IPDQ.F's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 104%.


Top Shareholders

Company Information

ImpediMed Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ImpediMed Limited
  • Ticker: IPDQ.F
  • Exchange: OTCPK
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$65.201m
  • Listing Market Cap: AU$46.423m
  • Shares outstanding: 1.03b
  • Website: https://www.impedimed.com

Number of Employees


Location

  • ImpediMed Limited
  • 50 Parker Court
  • Unit 1
  • Pinkenba
  • Queensland
  • 4008
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IPDASX (Australian Securities Exchange)YesOrdinary SharesAUAUDOct 2007
IPDQ.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 2007
IPDCHIA (Chi-X Australia)YesOrdinary SharesAUAUDOct 2007
39IDB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 2007

Biography

ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/30 00:07
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.